Rivaroxaban
First ODF approved across all 30 EU/EEA countries.
From ideation to market, ODFinity™ is Shilpa Medicare’s proprietary, fully integrated oral disintegrating film platform, a one-stop solution for ODF manufacturing.
ODFinity™ films dissolve in seconds, clean-label, flavourful and effortless to take. For our partners, that’s not just a better dose. It’s a more competitive product.








A conventional tablet travels through the digestive tract and liver, taking around 40 minutes to begin absorbing. An ODFinity™ film disintegrates on the tongue in seconds, designed for rapid onset and an effortless experience, no water required.
Most partners carry integration risk across formulation, manufacturing and regulatory. We remove it, one partner, one accountable platform, one path to market.
From Rivaroxaban, the first ODF approved across the EU, to CNS, men’s health, pain relief and clean-label nutraceuticals, we’ve formulated films across 10+ therapeutic areas. Rx, OTC and nutraceutical.
First ODF approved across all 30 EU/EEA countries.
Neurology & vestibular care.
Pain, fever & anti-nausea.
Clean-label daily wellness.
Among the first to commercialise Paracetamol and Ondansetron as oral disintegrating films.
ODFinity™ is built on the foundation of Shilpa Medicare, a global pharmaceutical company spanning APIs, formulations, biologics and CDMO services. Nearly four decades of scientific depth stand behind every film we make.
About Shilpa & ODFinity →White-label, private-label, CDMO and fully custom formulation, wherever you are in the journey, we’ll meet you there.
Partner with us





